Asymptomatic Plasmodium carrier (healthy people) Asymptomatic Plasmodium carrier
Conditions
Interventions
Administration of 5-aminolevulinic phosphate (5-ALA PO4) with sodium ferrous citrate (SFC) and zinc (Zn) to Asymptomatic Plasmodium carriers (healthy people)
Sponsors
Kano Shigeyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Participant who is able to give written informed consent 2.Male or female subject of 18 year to 65 year inclusive 3.Weighing 35 to 90 kg 4.Presence of malaria parasite of all species inclusive in blood confirmed by DNA amplification test 5.Women with child bearing potential willing to give consent for pregnancy test
Exclusion criteria
Exclusion criteria: 1.Participant with signs and symptoms of malaria 2.Known history of hypersensitivity, allergic or adverse reactions to 5-aminolevulinic acid, sodium ferrous citrate and Zn 3.Participant is pregnant or lactating women 4.Have taken any medication with antimalarial or antibiotic with antimalarial effect in previous 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Putative time-dependent decrease of Plasmodium DNA in the 5-ALA group compared to the placebo group at 3 months following enrolment as detected by DNA diagnostic method. | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c level at 1, 2, 3 months following enrolment | — |
Countries
Japan, Laos
Contacts
Public ContactMoritoshi Iwagami
Research Institute, National Center for Global Health and Medicine
Outcome results
None listed